Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) – Investment analysts at Jefferies Financial Group reduced their Q3 2022 EPS estimates for shares of Vanda Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 3rd. Jefferies Financial Group analyst C. Howerton now anticipates that the biopharmaceutical company will post earnings of $0.10 per share for the quarter, down from their prior forecast of $0.13. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is $0.30 per share.
Get Vanda Pharmaceuticals alerts:Vanda Pharmaceuticals (NASDAQ:VNDA – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.10). Vanda Pharmaceuticals had a return on equity of 2.19% and a net margin of 4.18%. The firm had revenue of $60.19 million during the quarter, compared to analysts' expectations of $58.00 million. During the same period in the previous year, the firm earned $0.15 EPS.
Separately, StockNews.com raised shares of Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday, June 3rd.Vanda Pharmaceuticals Stock Up 2.4 %
Shares of Vanda Pharmaceuticals stock opened at $10.55 on Monday. The firm's 50 day moving average price is $10.62 and its 200-day moving average price is $11.31. Vanda Pharmaceuticals has a 52-week low of $9.24 and a 52-week high of $21.44. The company has a market cap of $595.97 million, a P/E ratio of 52.75 and a beta of 0.47.
Insider Buying and Selling
In related news, Director Stephen Ray Mitchell sold 2,700 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $9.48, for a total value of $25,596.00. Following the completion of the sale, the director now directly owns 6,515 shares in the company, valued at approximately $61,762.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Stephen Ray Mitchell sold 2,700 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $9.48, for a total value of $25,596.00. Following the completion of the sale, the director now directly owns 6,515 shares in the company, valued at approximately $61,762.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard W. Dugan sold 6,500 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Tuesday, May 31st. The stock was sold at an average price of $9.85, for a total transaction of $64,025.00. Following the completion of the sale, the director now owns 68,387 shares of the company's stock, valued at $673,611.95. The disclosure for this sale can be found here. Insiders sold 11,439 shares of company stock worth $114,183 in the last three months. Corporate insiders own 6.10% of the company's stock.
Institutional Trading of Vanda Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Vanda Pharmaceuticals by 28.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,342 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 1,606 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Vanda Pharmaceuticals by 134.6% during the first quarter. Nisa Investment Advisors LLC now owns 8,540 shares of the biopharmaceutical company's stock worth $97,000 after buying an additional 4,900 shares in the last quarter. CI Investments Inc. acquired a new position in shares of Vanda Pharmaceuticals during the 1st quarter valued at about $107,000. Envestnet Asset Management Inc. acquired a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at about $110,000. Finally, Wedge Capital Management L L P NC acquired a new position in shares of Vanda Pharmaceuticals during the 1st quarter valued at about $117,000. 97.25% of the stock is currently owned by institutional investors and hedge funds.
About Vanda Pharmaceuticals
(Get Rating)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Stories
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- Can Airbnb Still Thrive in a Recession?
- What to Expect from the Markets in a Recession
- ConocoPhillips Shares Advance On Strong Q2 Revenue
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.